Single-dose oritavancin in the treatment of acute bacterial skin infections.
about
New Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound InfectionsOritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsDalbavancin for the treatment of acute bacterial skin and skin structure infectionsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidAcute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.Effects of Oritavancin on Coagulation Tests in the Clinical LaboratoryPharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.Vancomycin revisited - 60 years laterAntibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infectionOritavancin diphosphateThe multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department settingSingle-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management SettingOritavancin for acute bacterial skin and skin structure infections.Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact AnalysisMicrobiology and initial antibiotic therapy for injection drug users and non-injection drug users with cutaneous abscesses in the era of community-associated methicillin-resistant Staphylococcus aureusA Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound InfectionEarly Response in Cellulitis: A Prospective Study of Dynamics and Predictors.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Oritavancin: first global approval.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Oritavancin: A Long-Half-Life Lipoglycopeptide.The times they are a-changin': new antibacterials for skin and skin structure infections.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Next-generation nanoantibacterial tools developed from peptides.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Interventions for the prevention of recurrent erysipelas and cellulitis.New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.Oritavancin: a long-acting antibacterial lipoglycopeptide.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).
P2860
Q26749376-818BB52F-741A-47BD-AF71-91260EA13BB6Q26772897-A9FA2949-C635-47D6-A6E9-61111DCB4D8BQ26799598-5602AA47-9B67-42A6-B779-411335BF6B8EQ26799701-BD5E3E74-655E-4A59-87B1-B48C6258E04FQ28083116-D83B906B-C527-4379-8647-0D4C525AA04AQ30251580-ABBB78BB-2893-4B54-9A15-576824385E91Q30919516-AFA1A4E4-772A-4AFA-90E9-B18B6644A4D5Q33437580-2254B3F4-3CCE-448A-ABBE-FD908B2E30FDQ33438834-E87461C7-9AD0-4660-86C8-A77A53CFC583Q33732555-AD28A14E-D317-46DA-99CB-99CA6FF17E15Q34433066-32C9D39A-3029-4604-812B-95922963EE8FQ34447679-E061E700-CD20-4F02-A2C6-66C30A1F6575Q34478074-945F742A-3646-4A87-921D-1FD5DC173A0CQ35017990-323403F7-8163-4743-B3A0-86A5F688B6BCQ35057973-29AA216F-E0AD-41D8-A1D5-B2C24ADB3BAAQ35156014-9096EB8C-76B8-4CCD-8830-69CDAC1201F1Q35532355-97DA08BA-AC91-4E19-9840-7DF75D496329Q35656230-80FB03C8-1485-413A-8205-470A6C514BA9Q36066564-371979E8-7C06-47DB-B8CE-EAFB35C18526Q36086423-ED1F4ED7-432E-44F7-858F-83AB0CAFADB4Q36206165-5FBCFA77-52B5-4D06-8417-E53B4BA5E810Q36541737-121DD32A-382B-4331-BB2C-EBFEB188FEC1Q36832857-AD8E7204-3788-4050-A894-2149D4E9B3E5Q36948122-75257AE9-0DDD-4FD5-ABD9-926422FB7DA9Q37284156-0425A3E3-6CFF-4F0A-9FD2-3CB0B7EF4014Q38242081-0A0E9D67-A26E-4C97-B268-E2E2142E3824Q38252710-3002C657-295E-4F72-8884-6BF67D3749BEQ38347765-8847F4CD-0F2F-4832-A36B-7959D3DA1911Q38364691-F9086F4C-7D57-4E00-82B9-909E5519CF9EQ38434265-A94BEF84-875C-40D1-9C2C-F7A4E7D7195EQ38438503-DA90F9CF-C531-41F8-84A9-6BC193174E70Q38462842-42A71B03-AE35-4563-BC17-7A958AE4177EQ38501669-AC83AD0B-3039-4398-B736-0085EFD889B2Q38606618-3DF63BCC-BB43-4209-AC2B-70B97B732A28Q38615330-3147328A-D99E-4C71-AB52-786D2121B4E8Q38646905-C41653EC-C946-4101-B7EC-FA2DD515F0E4Q38717950-23E2B87A-8FE7-418F-B925-2B696391F206Q38768071-E8B74EF9-8975-4F57-BEB4-82C202F2C79CQ38830176-D2DBD50D-2FF5-4789-9986-3656C9F862DBQ38907793-1447CD34-CF4C-4D0D-A2E4-B4D9B33601B4
P2860
Single-dose oritavancin in the treatment of acute bacterial skin infections.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Single-dose oritavancin in the treatment of acute bacterial skin infections.
@en
type
label
Single-dose oritavancin in the treatment of acute bacterial skin infections.
@en
prefLabel
Single-dose oritavancin in the treatment of acute bacterial skin infections.
@en
P2093
P356
P1476
Single-dose oritavancin in the treatment of acute bacterial skin infections
@en
P2093
Antonio Perez
Ashwin Porwal
Christopher Lucasti
G Ralph Corey
Heidi Kabler
J Scott Overcash
Philip Giordano
Purvi Mehra
SOLO I Investigators
P304
P356
10.1056/NEJMOA1310422
P407
P50
P577
2014-06-01T00:00:00Z